Atlas Trials

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Clinical trial NCT04306887 · UNKNOWN

Trial details

NCT number
NCT04306887
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
Start date
2019-11-29
Primary completion
2022-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.